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The human microbiome comprises the genes and genomes of the microbiota that inhabit the body. We high-
light HumanMicrobiome Project (HMP) resources, including 600microbial reference genomes, 70million 16S
sequences, 700 metagenomes, and 60 million predicted genes from healthy adult microbiomes. Microbiome
studies of specific diseases and future research directions are also discussed.The NIH Human Microbiome
Project: A Community Resource
Though other terms such as endogenous
or commensal microbiota have been used
to describe the resident microorganisms
of the human body, these microbial com-
munities are more than a collection of
microbial cells to be counted. The human
microbiome encompasses the full com-
plement of microbial genes, gene prod-
ucts, and genomes of the microbiota
(which include bacteria, archaea, eukary-
otic viruses, bacteriophages, and eukary-
otic microbes) that call the human body
home and interact with the human host
to prime immunity and to maintain host
health. A revolution is occurring in our
understanding of the basis of many
common and complex diseases, infec-
tious and otherwise, as the role of the
human microbiome is incorporated into
our thinking about health and disease.
At 10–100 trillion cells, thousands of
species—and at least 20 million unique
microbial genes—the global microbiome
contributes to the health and mainte-
nance of the human superorganism. In-
terest in this system has been motivated
throughout the past decade by simul-
taneous advances in sequencing tech-
nologies and in microbial ecology, by the
recognition that the human genome is
only part of our genetic composition,
by an increased understanding that
the human host and microbiota have
coevolved. and that the microbiome is
intimately involved in the development
and maintenance of the immune system.
To catalyze the field, in October 2007
the NIH formally launched the 5 year
Human Microbiome Project (HMP) as
a community resource program (http://
commonfund.nih.gov/hmp), defined as
a research project ‘‘specifically devised
and implemented to create a set of data,reagents, or other material whose pri-
mary utility will be as a resource for the
broad scientific community’’ (http://www.
genome.gov/10506537). A marker paper
that described the HMP and its data
release policy serves as an outline of the
HMP resources under development (Pe-
terson et al., 2009).
Whereas other national and interna-
tional research initiatives focus on the mi-
crobiome of a specific part of the body,
the HMP is (1) surveying the microbiomes
across the bodies of a cohort of healthy
adults to produce a reference dataset
of baseline microbiomes, (2) developing
a catalog of microbial genome sequences
of reference strains, and (3) evaluating the
properties of microbiomes associated
with specific gastrointestinal tract, uro-
genital, and skin diseases in a collection
of Demonstration Projects. In addition,
three programs in technology develop-
ment, computational tools development,
and in the ethical and legal implications
of microbiome research were created to
support the field. A Data Analysis and
Coordination Center (DACC) was estab-
lished to support the sequencing by
the data processing and data analysis
efforts of the 100+ member HMP Re-
search Network Consortium and to serve
as a portal to the data sets, the reference
strain catalog, the computational tools,
and the other resources developed for
the larger research community (http://
www.hmpdacc.org).
The NIH NCBI BioProject page, the
public repository for the data, is an excel-
lent source to learn about the data types
produced in the program (http://www.
ncbi.nlm.nih.gov/bioproject/43021). There
are four projects listed under the HMP
program based on the four data types
produced: (1) targeted 16S ribosomal
RNA gene sequences, used as a taxo-Cell Host & Microbe 10nomic marker, produced from the healthy
adult cohort study; (2) whole-genome
shotgun metagenomic sequences (meta-
genome: all of the gene sequences from
one microbial community) produced
from the healthy adult cohort study; (3)
the reference strain microbial genome
sequences; and (4) data sets produced
in individual Demonstration Project activ-
ities. A conceptual diagram of the HMP
(Figure 1) depicts how the six initiatives
of the program interact through consor-
tium activities. The consortium, which
consists of the initiative research teams,
members from the larger scientific
community, and the NIH program staff,
interact through over 20 Working
Groups, biannual consortium meetings,
and a DACC-managed shared electronic
resource for consortial work. This work is
described under the three broad cate-
gories of (1) sample collection, (2) data
generation, and (3) data processing and
analysis (Figure 1). Details of the initia-
tives, the consortium activities, and the




The HMP has assembled a key reference
data set of microbial genome sequences
collected from the major body regions
of the human microbiome, primarily bac-
terial, although it also includes archaea,
viruses, bacteriophages, and eukaryotic
microorganisms. The project’s target
catalog of 3000 microbial genome se-
quences is intended as a reference for
the interpretation of the 16S ribosomal
RNA gene sequences, as well as a
scaffold for rapid assembly of metage-
nomic sequences determined from
the microbial communities. A publication
documenting the analysis of the first 178, October 20, 2011 ª2011 Elsevier Inc. 287
Figure 1. Conceptual Diagram of the HMP
The HMP is composed of six formal initiatives, shown around the circle; these
include Technology Development; Ethical, Legal, and Social Issues; Genome
Centers; the Data Analysis and Coordination Center; Computational Tools;
and the Demonstration Projects. These initiatives interact through the activities
of the 100+ member HMP Research Network Consortium, which also include
members of the larger scientific community and NIH program staff. The
consortium activities, shown in the three interior bubbles, include (1) sample
collection, which includes the clinical protocols development and collection
of microbiome specimens and nucleic acid sample preparation from the spec-
imens in the healthy cohort study and in the Demonstration Projects; (2) data
generation, which includes all of the sequencing activities for the healthy
cohort, Demonstration Projects, and the reference strain microbial genomes,
and (3) data analysis, which includes the extensive data processing, bench-
marking, and quality-control steps needed to produce data for public release
and for the analysis of microbiome sequence data by the consortium. The con-
necting lines graphically depict the major interactions between the initiatives.
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recently published (Nelson
et al., 2010); just this subset
of the catalog described
over 550,000 predicted
genes, 30,000 of which
were novel.
As of this writing, almost
1900 microbial strains have
been sequenced or are in pro-
gress for the HMP reference
strain catalog (http://www.
hmpdacc-resources.org/hmp_
catalog). Approximately 600 of
these are available in GenBank
(http://www.ncbi.nlm.nih.gov/
bioproject/28331), and cul-
tures of the corresponding
reference strains are available
at the HMP Strain Repository






The secondmajor resource of
the HMP is the largest study
to date of the microbiomes of
five major areas of the body
of healthy adults (airway,skin, oral cavity, gastrointestinal tract,
and vagina; see Figure 2). Several specific
body sites were sampled within each
major area (18 in total), and as the volun-
teers were clinically verified as being free
of overt disease in all of the body sites,
this study is known as the healthy adult
cohort study.
Extensive exclusion criteria for selec-
tion of healthy volunteers were developed
based on a combination of health history
(particularly systemic disorders), use of
antibiotics, probiotics, or immunomodu-
lators, as well as physical examinations
of each volunteer. Volunteers were not
always initially free of disease in all body
sites; a common example of this was
with the oral cavity, where otherwise
healthy volunteers had dental caries and
required treatment before re-entering the
study. Three hundred adult volunteers
were enrolled at two clinical centers
(Baylor College of Medicine, Houston,
TX; Washington University, St. Louis,
MO); these included equal numbers of
18- to 40-year-old men and women,
20% of whom identified themselves as a
racial minority and 11% of whom identi-288 Cell Host & Microbe 10, October 20, 201fied themselves as Hispanic. Exclusion
and inclusion criteria, clinical sampling
procedures, and the corresponding clin-
ical metadata can be found at the NCBI
database of Genotypes and Phenotypes
(dbGaP, http://www.ncbi.nlm.nih.gov/
projects/gap/cgi-bin/study.cgi?study_id=
phs000228). Of the 300 volunteers in this
study, 279 were sampled twice and 100
were sampled a third time over approxi-
mately 22 months. Among the 18 total
body sites sampled, the oral cavity had
the largest number of sites (nine; see
Figure 2), and all were directly sampled
except for the gut tract, for which stool
served as a proxy. Blood was collected
for serum and for future whole-genome
sequencing, and lymphocytes were har-
vested for cell lines; these specimens
are being held at the NHGRI Coriell
Repository for future distribution. The
genome centers at four institutions (Bay-
lor College of Medicine, Broad Institute,
J. Craig Venter Institute, and Washington
University at St. Louis) carried out the
sequencing activities.
Of the >11,000 primary microbiome
specimens collected for the full cohort,1 ª2011 Elsevier Inc.all have been sequenced for
the 16S rRNA gene taxo-
nomic marker. Metagenomic
sequence data has addition-
ally been generated from ap-
proximately 750 of the nucleic
acid samples, comprising of 7
body sites from 100 subjects.
About 50% of the full set of
16S data and 90% of the
metagenomic data was tar-
geted by the Consortium for
a global analysis. The data
sets for the global analysis
comprise over 70 million
16S rRNA gene sequences,
and after removing contami-
nating human sequence (on
average 50% of total meta-
genomic sequence) over 3.5
terabases (Tbp) of whole-
genome shotgun metage-
nomic data. Although only
about 60% of these metage-
nomic sequences could be
aligned to a reference micro-
bial genome sequence, anno-
tation resulted in over 60
million predicted genes (i.e.,
open-reading frames). The
human microbiome clearlycontains a rich diversity of genetic infor-
mation and function, much of it uncharac-
terized and often completely novel.
As of this writing, 126 publications in
PubMed cite the HMP. The HMP Consor-
tium is currently finalizing three major
publications: the first, a description of
the clinical protocol for microbiome spec-
imen sampling; the second, a catalog
of the HMP and its data products; and
the third, a large-scale, global analysis
of the healthy adult cohort study using
the data sets described above. These
results describe the range of normal
microbial variation among healthy adults
in a Western population. The microbiota
differed among individuals when commu-
nities were analyzed at several taxonomic
levels (genera, species, strains), or even
when individual loci and genomic islands
were considered. Differences in microbial
membership were even greater between
body sites than between individuals;
as one example, even adjacent oral sur-
faces separated by only millimeters
or less in distance within the same sub-
ject exhibited strikingly different commu-
nity structures. However, even though
Figure 2. Schematic of the Body Sites Sampled for the HMP Healthy Adult Cohort Study
Three hundred individuals were sampled across a total of 18 body sites in 5 major body regions to collect
microbiome specimens for sequence analysis. The oral cavity, skin, airway, and gastrointestinal tract
regions were sampled in males, and the vagina was additionally sampled in females as the fifth major
body region for the study. Eight distinct soft and hard surface sites were sampled in the oral cavity with
saliva representing the ninth oral site, four sites were sampled on the skin, and three sites were sampled
in the vagina. The airway was represented by a pooled sample of the anterior nares, and the distal gut tract
region was represented by one sample of stool. Over 11,000 primary specimens for sequencing were
collected in this study. (Figure adapted from Sitepainter visualization tool figure from Knight, Perrung,
and Gonzalez, University of Colorado; tool available at http://www.hmpdacc/sp).
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potential metabolic capabilities encoded
in these communities’ metagenomes
were much more constant, both among
body sites and between individuals. That
is, although the microbiota in the healthy
microbiome varied among individuals,
the functions the microbiota are equipped
to carry out remain remarkably stable
within each body site. In addition to
these findings, approximately 15–20
companion papers addressing specific
questions about microbial prevalence,
ecology, metabolism, and signaling func-
tions, and the computational and analyt-
ical tools developed for the healthy cohort
data are in review and will accompany
the three main consortium publications.
Demonstration Projects
A third key resource from this activity is
the Demonstration Projects, designed to
evaluate microbiome characteristics in
disease states with putative microbiome
associations. Many complex diseases
appear to have amicrobiome component,
and these projects were designed to
characterize the microbiome in such
cases in order to develop a reference
data set of microbiome properties associ-
ated with specific disease and clinical
phenotypes.Eleven Demonstration Project studies
have been launched to date, including
six projects on microbiome-associated
gastrointestinal diseases (Crohn’s dis-
ease, ulcerative colitis, pediatric inflam-
matory bowel syndrome, neonatal ne-
croticizing enterocolitis, and esophageal
adenocarcinoma), three on urogenital
conditions (changes associated with
bacterial vaginosis, reproductive history,
sexual history, and circumcision), and
two on microbiome-associated skin dis-
eases (eczema and psoriasis). The age
groups across these studies range from
birth to over 50 years old, and the size of
some study cohorts approach 500 indi-
viduals. Almost all of the studies include
16S and shotgun metagenomic sequenc-
ing, and some also include functional data
from the microbiome such as gene
expression, microbial community proteo-
mics, or metabolomics. Details of each
project’s purpose, experimental design
and scope, data quality policies, antici-
pated analyses, and data release plans
can be found in marker papers at Nature
Precedings (http://precedings.nature.com/
collections/human-microbiome-project).
Early results from some of these studies
are showing that a characteristic micro-
biome community appears to be associ-Cell Host & Microbe 10ated with each specific disease: three
examples where this has been reported
are neonatal necroticizing enterocolitis
(NEC) (Wang et al., 2009), gastric esopha-
geal reflux disease (GERD) (Yang et al.,
2009), and pediatric irritable bowel
syndrome (IBS) (Saulnier et al., 2011).
These microbial signatures often include
both taxonomic markers, such as altered
overall community composition, and
functional markers, such as differences
in specific proteins identified from within
the total protein content (i.e., metapro-
teome) of the disease-associated micro-
bial community, providing a potential
suite of markers for future development
of diagnostic or prognostic applications.
In addition, some microbial biomarkers
may precede the disease state, possibly
allowing earlier detection and interven-
tion. For example, GERD is characterized
by a series of diseases, starting with re-
flux esophagitis, progressing to Barrett’s
esophagus in about 20% of cases, and,
in rare cases, proceeding to the devel-
opment of esophageal adenocarcinoma.
The Pei/Nelson foregut microbiome
esophageal adenocarcinoma study has
found that those patients who go on to
develop adenocarcinoma appear to
have very similar foregut microbiomes
to those patients with the intermediate
stage of the disease (Barrett’s esoph-
agus), suggesting that microbiome com-
position in Barrett’s esophagus may be
one potential precursor marker for the
cancer (Yang et al., 2009). In this case, it
may be possible to develop diagnostic
biomarkers for adenocarcinoma far be-
fore the cancer develops. The Demon-
stration Projects data sets and descrip-
tions can be found at NCBI Bioprojects
(http://www.ncbi.nlm.nih.gov/bioproject/
46305).
Future Directions for Human
Microbiome Research
We are at a pivotal point in the field of
human microbiome research. The HMP
has provided an extensive resource of
datasets, computational tools, clinical
methods, and scientific approaches to
the study of the human microbiome.
Here, we suggest a few key research
areas to move the field forward.
We do not yet have a mechanistic
understanding of the basic factors that
regulate microbiome development during
foundational events early in a person’s, October 20, 2011 ª2011 Elsevier Inc. 289
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acquired anew from the environment at
birth (Dominguez-Bello et al., 2010) and
that during early years, the maturing
immune system (Round and Mazmanian,
2009), diet, and the assembling microbial
community interact to establish the mi-
crobiome (Koenig et al., 2011). However,
the roles of the source inoculum in the
maturing microbiome are not yet clear—
nor are those of the host immune system
in regulating colonization by specific
members of the microbiota, of the micro-
biome in regulating host tissue develop-
ment, of the microbiome in resisting colo-
nization by new microbes, or those of
breastmilk and the infant diet on early
microbial colonization of the gut and other
body habitats.
Further, it appears that the microbiome
retains much of its dynamic quality
throughout life and is highly personalized
(Costello et al., 2009), indicating that
we may not yet understand what consti-
tutes a healthy or, more generally, normal
microbiome, particularly over the full life-
time of an individual (Claesson et al.,
2011). Microbial transmissionmight occur
environmentally, internally within and
among body habitats, or epidemiologi-
cally through the interactions of human
and other vertebrate hosts. We do not
yet understand the significance of inter-
actions between early microbiome events
and microbiome function and change
throughout life. For example, some stud-
ies have suggested that a disturbed
microbiome at infancy, e.g., through anti-
biotic use, may predispose one to aller-
gies later in life (Bisgaard et al., 2011);
other disorders (e.g., Crohn’s disease,
asthma, type 1 diabetes, multiple scle-
rosis, celiac disease, and others) have
also been associated with a disturbed,
altered, or impoverished microbiome in
infancy.
In addition, host genetics, culture, and
ancestry remain largely unexplored areas
of interactionwith the humanmicrobiome.
To date, with some exceptions (e.g., De-
Filippo et al., 2010), most microbiome
studies have not included significant
populations of non-European ancestry
to capture the breadth of factors that
may contribute to microbiome assembly
or stability. Further, no major microbiome
study has included host genetics; it is
imperative we begin to consent volun-
teers as broadly as possible in our efforts290 Cell Host & Microbe 10, October 20, 201to include all of the factors that may
contribute to the microbiome. Results
from genome-wide association studies
over the past decade demonstrate it will
be crucial to leverage multiple large
populations with well-understood struc-
ture and prospectively determined phe-
notypes in order to derive robust genetic
associations with quantitative micro-
biome traits. Given that variation in the
microbiome appears to be far greater
than human genetic variability, repeated
studies in each target population will be
needed to identify keystone microbiome
signatures against a complex and con-
textually dependent background.
Though the microbiome of each region
of the body is unique to and important
for the health of the host, the gastrointes-
tinal microbiome may arguably be con-
sidered the ‘‘cardinal microbiome,’’ as it
is the community that most directly inter-
acts with the host immune system (Round
andMazmanian, 2009), as well as contrib-
uting to food digestion and energy supply
for host cell metabolism. These functions
also include regulation of the host and of
other microbiomes through signaling
molecules and metabolites that circulate
throughout the body, although the extent
to which such functions might also be
performed by local microbiomes is not
yet clear. There has been considerable
interest in understanding whether the hu-
man gut microbiome can be categorized
into predominant types, or ‘‘enterotypes’’;
patterns of variability are reproducible
across human populations (Arumugam
et al., 2011), although this variability
appears to be associated with long-term
diet (De Filippo et al., 2010) but not
short-term diet (Wu et al., 2011). A
concerted effort to study the relationship
between diet and the microbiome in
human populations would be an impor-
tant foundational effort, as would an
investigation of the systemic role of the
gut community and how it interacts with
the host tissues and with other microbial
communities across the body. As the gut
microbiome in particular appears to be
amenable to manipulation (Manichanh
et al., 2010), an ecological understanding
based on these studies may hold the
potential for disease treatment and,
perhaps most importantly, prevention
through microbiome therapeutics.
Just as advances in sequencing tech-
nologies paved the way for the charac-1 ª2011 Elsevier Inc.terization of microbiome composition,
new technologies are now needed to
study microbiome function and its inter-
actions with the host. These new
resources should include technology
development for high-throughout meth-
odologies such as metatranscriptomics,
metaproteomics, and metabolomics as
well as new model systems for the study
of microbiome function. Opportunities
for collaboration in the development of
some of these new resources may now
be on the horizon. For example, the NIH
will soon be initiating a new program in
metabolomics to include technology de-
velopment (http://commonfund.nih.gov/
Metabolomics). This activity would pro-
vide an ideal opportunity to collaborate
in the development of methodologies
for microbiome metabolomics, as we will
specifically need to move beyond com-
position to an understanding of micro-
biome function and its interaction with
the host if the microbiome is to be fully
integrated into the study of human health
and disease.
Furthermore, cohort studies could
serve as one platform from which nu-
merous investigations could address mi-
crobiome development, variability of the
microbiome across populations, temporal
changes, and functional properties in
response to diet or disease. With proper
consent and privacy safeguards in place,
the genome sequences of the cohort
members themselves would provide in-
valuable information for integration with
the microbiome assays. Initial opportuni-
ties in this area are already becoming
available; for example, a collaboration be-
tween the NIH, the CDC, and the EPA is
conducting the National Children’s Study
(http://www.nationalchildrensstudy.gov),
which will follow 100,000 children from
birth to 21 years. This cohort study is
designed to examine the effect of the
environment on the health and develop-
ment of children. Young Lives, a British-
led international study of childhood
poverty (http://www.younglives.org.uk) is
following 12,000 children in four devel-
oping countries—Ethiopia, India, Peru,
and Vietnam. These and other cohort
studies could provide ideal frameworks
from which to analyze the microbiome
from birth in diverse populations.
It is perhaps useful to recall here that
the microbiome is not inherited but
acquired anew each generation. This
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mensal and beneficial microbes (as well
as pathogens) that contribute to the mi-
crobiome may be found not only in other
hosts but also in the environment. Appre-
ciation for the continuum that exists be-
tween the host and the environment is
growing (http://www.onehealthinitiative.
com) and should serve as a guiding prin-
ciple in future studies of the microbiome.
In fact, opportunities may already be on
the horizon for initiatives that bridge the
host with the environment. For example,
joint agency activities such as the newly
formed ‘‘USDA-NSF-NIH Research Coor-
dination Working Group,’’ which is
focusing on possible programs in the
areas of obesity, nutrition, microbiome,
and plant genomics, could place these
initiatives in the appropriate environ-
mental framework.
Finally, for these studies to benefit the
broadest community, these activities will
require a flexible and user-friendly infra-
structure that links diverse aspects of
the microbiome including microbial com-
position and function, and host pheno-
type and genotype. All of these must be
associated with appropriate, ready-to-
use computational and analytical tools
that are accessible to a broad spectrum
of microbiological, ecological, and bio-
informatic expertise. In fact, it will be the
routine access and use of this network
of data and tools that will move this field
into the clinical realm. Diverse popula-
tions should be included in all of these
studies in order to circumscribe and relate
the fundamental properties of the micro-biome with other features of the human
hosts themselves. High-throughput meth-
odologies to measure microbiome func-
tion, including interactions among the
microbes, among microbial communities,
and between microbe and host—in con-
junction with large cohort studies and all
supported by a well-designed infrastruc-
ture—will establish the needed resources
and data for future research and applica-
tion of the microbiome in health and in
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